Zomedica Corp ZOM shares are trading lower by 13.6% at $0.49 Thursday morning after the company reported second-quarter earnings results. Zomedica reported quarterly losses of 1 cent per share.
Zomedica reported revenue for the three and six months ended June 30, 2021 of $15,693 and $29,817, respectively, and resulted from the sale of the company's TRUFORMA® products and associated warranties.
Zomedica had cash and cash equivalents of approximately $276.2 million as of June 30, 2021, compared to approximately $29.1 million as of June 30, 2020. Zomedica says the increase in cash during the three months ended June 30, 2021 is mainly a result of the cash flows from financing activities, partially offset by cash flows used in operating and investing activities.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Zomedica has a 52-week high of $2.91 and a 52-week low of $0.06.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
